Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK has received Orphan Drug Designation in the U.S. for this potential use. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans.
Company profile
Ticker
FENC
Exchange
Website
CEO
Rostislav Raykov
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
ADHEREX TECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
Oxiquant, Inc. • Cadherin Biomedical Inc. • Fennec Pharmaceuticals (EU) Limited ...
FENC stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
31 Jan 23
8-K
Other Events
25 Jan 23
424B3
Prospectus supplement
15 Dec 22
EFFECT
Notice of effectiveness
13 Dec 22
CORRESP
Correspondence with SEC
8 Dec 22
UPLOAD
Letter from SEC
7 Dec 22
S-3
Shelf registration
1 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States
17 Oct 22
8-K
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment
26 Sep 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 29.75 mm | 29.75 mm | 29.75 mm | 29.75 mm | 29.75 mm | 29.75 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 2.63 mm | 1.72 mm | 1.67 mm | 1.21 mm |
| Cash used (since last report) | n/a | n/a | 10.77 mm | 7.04 mm | 6.83 mm | 4.94 mm |
| Cash remaining | n/a | n/a | 18.98 mm | 22.71 mm | 22.92 mm | 24.81 mm |
| Runway (months of cash) | n/a | n/a | 7.2 | 13.2 | 13.7 | 20.5 |
Institutional ownership, Q3 2022
43.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 34 |
| Opened positions | 10 |
| Closed positions | 4 |
| Increased positions | 3 |
| Reduced positions | 10 |
| 13F shares | Current |
|---|---|
| Total value | 93.40 mm |
| Total shares | 11.36 mm |
| Total puts | 476.20 k |
| Total calls | 351.00 k |
| Total put/call ratio | 1.4 |
| Largest owners | Shares | Value |
|---|---|---|
| Southpoint Capital Advisors | 4.08 mm | $33.03 mm |
| Sonic Fund II | 2.41 mm | $19.50 mm |
| Avoro Capital Advisors | 1.20 mm | $9.72 mm |
| Solas Capital Management | 1.13 mm | $9.16 mm |
| DG Capital Management | 1.01 mm | $8.14 mm |
| 683 Capital Management | 384.82 k | $3.12 mm |
| Millennium Management | 249.34 k | $2.02 mm |
| Harbert Fund Advisors | 189.75 k | $1.54 mm |
| EAM Investors | 176.82 k | $1.43 mm |
| Tamarack Advisers | 175.00 k | $1.42 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 Dec 22 | Robert Andrade | Common shares | Sell | Dispose S | No | Yes | 9.6122 | 5,500 | 52.87 k | 149,721 |
| 30 Dec 22 | Raykov Rosty | Common shares | Sell | Dispose S | No | No | 9.6135 | 8,400 | 80.75 k | 217,838 |
| 30 Dec 22 | Raykov Rosty | Common shares | Sell | Dispose S | No | No | 9.6586 | 1,600 | 15.45 k | 226,238 |
| 29 Dec 22 | Robert Andrade | Common shares | Sell | Dispose S | No | Yes | 9.5748 | 5,500 | 52.66 k | 155,221 |
| 29 Dec 22 | Raykov Rosty | Common shares | Sell | Dispose S | No | No | 9.65 | 5,000 | 48.25 k | 227,838 |
| 28 Dec 22 | Robert Andrade | Common shares | Sell | Dispose S | No | Yes | 9.6145 | 11,000 | 105.76 k | 160,721 |
| 28 Dec 22 | Raykov Rosty | Common shares | Sell | Dispose S | No | No | 9.59 | 13,740 | 131.77 k | 232,838 |
| 17 Nov 22 | Rallis Chris A | Common Shares | Sell | Dispose S | No | Yes | 7.99 | 333 | 2.66 k | 30,018 |
| 20 Oct 22 | Rallis Chris A | Common Shares | Payment of exercise | Dispose F | No | Yes | 8.26 | 2,068 | 17.08 k | 30,351 |
| 20 Oct 22 | Rallis Chris A | Common Shares | Option exercise | Acquire M | No | No | 1.05 | 4,762 | 5.00 k | 32,419 |
News
HC Wainwright & Co. Reiterates Buy on Fennec Pharmaceuticals, Maintains $18 Price Target
26 Jan 23
US Stocks Open Lower; Dow Dips 250 Points
25 Jan 23
Expert Ratings for Fennec Pharmaceuticals
22 Nov 22
What 4 Analyst Ratings Have To Say About Fennec Pharmaceuticals
22 Nov 22
4 Analysts Have This to Say About Fennec Pharmaceuticals
22 Nov 22
Press releases
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
31 Jan 23
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
25 Jan 23
Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update
11 Nov 22